<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03032640</url>
  </required_header>
  <id_info>
    <org_study_id>TRIMDFH 982524</org_study_id>
    <nct_id>NCT03032640</nct_id>
  </id_info>
  <brief_title>Interactions of Human Gut Microbiota With Intestinal Sweet Taste Receptors</brief_title>
  <acronym>ISTAR-micro</acronym>
  <official_title>Interactions of Human Gut Microbiota With Intestinal Sweet Taste Receptors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Translational Research Institute for Metabolism and Diabetes, Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Translational Research Institute for Metabolism and Diabetes, Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to collect data to examine whether short-term consumption of
      non-caloric artificial sweeteners (NCASs), such as saccharin, can lead to changes in blood
      sugar levels and in the composition of the bacteria in the large intestine.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood analyzed by way of NOVA StatStrip Meter and Milliplex Map Kit.</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Short chain fatty acid analyses</measure>
    <time_frame>6 weeks</time_frame>
    <description>Stool sample aliquoted and frozen by way of ribosomal sequencing, which will be used to determine what bacteria is in the fecal sample.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Group 1- Healthy Lean subjects</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 1 will receive Sodium Saccharin 200mg capsule, 2x/day, Day 1-14</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2- Healthy Lean subjects</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 2 will receive Placebo 500mg capsule, 2x/day, Day 1-14</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3- Healthy Lean subjects</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 3 will receive Sodium Saccharin 200mg + lactisole 335mg capsule, 2x/day, Day 1-14</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4- Healthy Lean subjects</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 4 will receive Lactisole 335mg capsule, 2x/day, Day 1-14</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Oral Glucose Tolerance Test (OGTT)</intervention_name>
    <description>Once we test the fasting plasma glucose (after an overnight fast), subject will receive a 75g glucose beverage they will have to drink within 5 minutes. Then after drinking the beverage, 8 blood samples will be collected through the IV catheter, over the next 3 hours.</description>
    <arm_group_label>Group 1- Healthy Lean subjects</arm_group_label>
    <arm_group_label>Group 2- Healthy Lean subjects</arm_group_label>
    <arm_group_label>Group 3- Healthy Lean subjects</arm_group_label>
    <arm_group_label>Group 4- Healthy Lean subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Assessment of dietary compliance</intervention_name>
    <description>Assessment of consumption of non-caloric artificial sweeteners</description>
    <arm_group_label>Group 1- Healthy Lean subjects</arm_group_label>
    <arm_group_label>Group 2- Healthy Lean subjects</arm_group_label>
    <arm_group_label>Group 3- Healthy Lean subjects</arm_group_label>
    <arm_group_label>Group 4- Healthy Lean subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Stool sampling</intervention_name>
    <description>Subjects will provide a stool sample.</description>
    <arm_group_label>Group 1- Healthy Lean subjects</arm_group_label>
    <arm_group_label>Group 2- Healthy Lean subjects</arm_group_label>
    <arm_group_label>Group 3- Healthy Lean subjects</arm_group_label>
    <arm_group_label>Group 4- Healthy Lean subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sodium Saccharin</intervention_name>
    <arm_group_label>Group 1- Healthy Lean subjects</arm_group_label>
    <arm_group_label>Group 3- Healthy Lean subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Group 2- Healthy Lean subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Lactisole</intervention_name>
    <arm_group_label>Group 3- Healthy Lean subjects</arm_group_label>
    <arm_group_label>Group 4- Healthy Lean subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Able to provide written informed consent

          2. Age 18-45 years

          3. Weight stable (± 3 kg) during the 6 months prior to enrollment

          4. BMI ≤ 25 kg/m2

          5. Consumption of less than a can of diet beverage or a spoonful of NCASs weekly (or each
             equivalent from foods) during the past month

        Exclusion Criteria:

          1. Known coronary artery disease, angina or congestive heart failure

          2. Type 1 or Type 2 Diabetes (A1c ≥6.5%)

          3. Bleeding disorders

          4. Hemoglobin level &lt; 12.5 g/dL for women; hemoglobin level &lt; 13.0 g/dL for men

          5. Acute or chronic infections

          6. Hepatitis and/or cirrhosis

          7. Severe asthma or chronic obstructive pulmonary disease

          8. Renal insufficiency or nephritis (creatinine &gt; 1.6 mg/dl)

          9. Prior bariatric surgery

         10. Inflammatory bowel disease or malabsorption

         11. Cancer within the last 3 years (except non-melanoma skin cancer or treated cervical
             carcinoma in situ)

         12. Psychiatric disorders or eating disorders

         13. Cushing's disease or syndrome

         14. Untreated or inadequately controlled hypo- or hyperthyroidism (abnormal TSH)

         15. Active rheumatoid arthritis or other inflammatory rheumatic disorder

         16. Pregnant or nursing women

         17. Smoking (smoking within the past 3 months)

         18. Less than 4 bowel movements per week

         19. Known hypersensitivity to saccharin, lactisole or any of its excipients.

             Excluded medications include but are not limited to:

         20. Anti-diabetic agents

         21. Oral, injected or chronic topical steroids (inhaled steroids for mild asthma are
             acceptable)

         22. Antibiotic use (within the past 3 months)

         23. Other drugs known to affect immune or metabolic function

         24. Orlistat, phentermine, topiramate or other weight loss or anorectic agents (tricyclic
             antidepressants, atypical antipsychotics or other psychiatric drugs with effects on
             body weight)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Pratley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Translational Research Institute for Metabolism and Diabetes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Quianna Stokes- Washington</last_name>
    <phone>407-303-7100</phone>
    <email>trimd@flhosp.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Florida Hospital Translational Research Institute for Metabolism and Diabetes</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Quianna Stokes-Washington</last_name>
      <phone>407-303-7100</phone>
    </contact>
    <investigator>
      <last_name>Richard Pratley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.tri-md.org</url>
    <description>Website for Translational Research Institute for Metabolism and Diabetes</description>
  </link>
  <reference>
    <citation>Swithers SE. Artificial sweeteners produce the counterintuitive effect of inducing metabolic derangements. Trends Endocrinol Metab. 2013 Sep;24(9):431-41. doi: 10.1016/j.tem.2013.05.005. Epub 2013 Jul 10.</citation>
    <PMID>23850261</PMID>
  </reference>
  <reference>
    <citation>Tilg H, Kaser A. Gut microbiome, obesity, and metabolic dysfunction. J Clin Invest. 2011 Jun;121(6):2126-32. doi: 10.1172/JCI58109. Epub 2011 Jun 1. Review.</citation>
    <PMID>21633181</PMID>
  </reference>
  <reference>
    <citation>Suez J, Korem T, Zeevi D, Zilberman-Schapira G, Thaiss CA, Maza O, Israeli D, Zmora N, Gilad S, Weinberger A, Kuperman Y, Harmelin A, Kolodkin-Gal I, Shapiro H, Halpern Z, Segal E, Elinav E. Artificial sweeteners induce glucose intolerance by altering the gut microbiota. Nature. 2014 Oct 9;514(7521):181-6. doi: 10.1038/nature13793. Epub 2014 Sep 17.</citation>
    <PMID>25231862</PMID>
  </reference>
  <reference>
    <citation>Saccharin and its salts. IARC Monogr Eval Carcinog Risks Hum. 1999;73:517-624. Review.</citation>
    <PMID>10804968</PMID>
  </reference>
  <reference>
    <citation>Pantarotto C, Salmona M, Garattini S. Plasma kinetics and urinary elimination of saccharin in man. Toxicol Lett. 1981 Dec;9(4):367-71.</citation>
    <PMID>7330898</PMID>
  </reference>
  <reference>
    <citation>Sweatman TW, Renwick AG. The tissue distribution and pharmacokinetics of saccharin in the rat. Toxicol Appl Pharmacol. 1980 Aug;55(1):18-31.</citation>
    <PMID>7191585</PMID>
  </reference>
  <reference>
    <citation>Renwick AG. The metabolism of intense sweeteners. Xenobiotica. 1986 Oct-Nov;16(10-11):1057-71. Review.</citation>
    <PMID>3541395</PMID>
  </reference>
  <reference>
    <citation>Arnold DL, Krewski D, Munro IC. Saccharin: a toxicological and historical perspective. Toxicology. 1983 Jul-Aug;27(3-4):179-256. Review.</citation>
    <PMID>6353664</PMID>
  </reference>
  <reference>
    <citation>Sweatman TW, Renwick AG, Burgess CD. The pharmacokinetics of saccharin in man. Xenobiotica. 1981 Aug;11(8):531-40.</citation>
    <PMID>7303723</PMID>
  </reference>
  <reference>
    <citation>Renwick AG. The disposition of saccharin in animals and man--a review. Food Chem Toxicol. 1985 Apr-May;23(4-5):429-35. Review.</citation>
    <PMID>3891556</PMID>
  </reference>
  <reference>
    <citation>Evaluation of certain food additives and contaminants. Forty-first report of the Joint FAO/WHO Expert Committee on Food Additives. World Health Organ Tech Rep Ser. 1993;837:1-53.</citation>
    <PMID>8266711</PMID>
  </reference>
  <reference>
    <citation>Food and Agriculture Organization World Health Organization. Evaluation of certain food additives. Fifty-ninth report of the Joint FAO/WHO Expert Committee on Food Additives. World Health Organ Tech Rep Ser. 2002;913:i-viii, 1-153, back cover.</citation>
    <PMID>12677645</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2016</study_first_submitted>
  <study_first_submitted_qc>January 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2017</study_first_posted>
  <last_update_submitted>February 13, 2018</last_update_submitted>
  <last_update_submitted_qc>February 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glucose</keyword>
  <keyword>Sweet taste receptors</keyword>
  <keyword>Artificial sweeteners</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

